Skip to content
★ Sign in to follow
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.- B - H Shares logo

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.- B - H Shares Stock: price and insider trades · Hong Kong

HK·Mcap HK$22B

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.- B - H Shares: what insiders have been doing

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.- B - H Shares is a listed company. Its insiders report their share dealings to HKEX. The last twelve months, up to 8 November 2026, brought 3 filings signed by 3 insiders.

No insider bought on the market over the period, while 3 insiders filed 3 sales totalling €723k. Biggest ticket of the year: €361k, sold by SHEN Yuelei and made public on 16 June 2026.

For context, the typical company on the same exchange (median of 750 companies) published 5 filings over the same period, against 3 filings here. The full history, which starts in 2026, counts no purchases against 3 sales.

Between a trade and the moment it shows up on HKEX, the median delay is 1 day. Until a filing is published, the market cannot know about the trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.

This summary is built from HKEX disclosures alone and does not predict where the share price will go.

Insider Decl.
3
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€723,276
3 ops. · all time

Who traded when

BuySale
Li Yan1 sale
NI Jian1 sale
SHEN Yuelei1 sale

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 12,294 of 26,897 companies
53.8
score / 100
Value
29
Quality
78
FCF yld1.5%
Earn yld0.9%
EV/EBITDA45.4x
ROE21%
Gross mgn76%
Net mgn13%
Debt/EBITDA1.4x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$49.66
Analyst consensus
1 analysts
1.00/5
HK$62.93Target HK$62.93(+27%)HK$62.93
Income statement
RevenueHK$1.4B
Gross profitHK$1B76% margin
EBITDAHK$419.5M30% margin
Net incomeHK$173.2M21.6% margin
Valuation
PER (trailing)52.3x
PER (forward)42.4x
P/Book7.8x
Beta0.01
Balance sheet & cash
Market capHK$22B
Total debtHK$584.1M
Free Cash FlowHK$282.4M
Debt / Equity29%
Profitability & ownership
ROE22.0%
ROA8.6%
% insiders24.3%
% institutions53.4%
Last declaration on 18 September 2026
Declarations3 total
  • ▼
    DirectorExecutives
    16,198 HKD26HKEX
    260 shares@ HK$62.300.0001% mcap100.0% of flowShareXHKGHKEX:DA20260918E00087
  • ▼
    DirectorExecutives
    3M HKD31HKEX
    80,000 shares@ HK$40.959100.0% of flowShareXHKGHKEX:DA20260616E00306
  • ▼
    DirectorExecutives
    3M HKD31HKEX
    80,000 shares@ HK$40.959100.0% of flowShareXHKGHKEX:DA20260616E00312

3 of 3 declarations

About Biocytogen Pharmaceuticals (Beijing) Co., Ltd.- B - H Shares

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a company focused on the research and development of pharmaceuticals, with an emphasis on biotechnology. It is listed under the H Shares category on the Hong Kong Stock Exchange.